Login to Your Account



Clinic Roundup


Monday, January 23, 2012
• Idera Pharmaceuticals Inc., of Cambridge, Mass., said a Phase Ib trial of Toll-like receptor 9 agonist IMO-2055 plus Tarceva (erlotinib, Astellas Pharma Inc. and Roche AG) and Avastin (bevacizumab, Roche AG) in refractory non-small-cell lung cancer patients showed the combination was well tolerated and resulted in a disease control rate of 79 percent, median progression-free survival (PFS) of 5.6 months and median overall survival (OS) of 16 months.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription